1.
NPJ Precis Oncol
; 6(1): 86, 2022 Nov 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36418474
RESUMO
The combination of KRAS G12C inhibitors with EGFR inhibitors has reproducibly been shown to be beneficial. Here, we identify another benefit of this combination: it effectively inhibits both wild-type and mutant RAS. We believe that targeting both mutant and wild-type RAS helps explain why this combination of inhibitors is effective.